Pegylated liposomal doxorubicin in recurrent serous carcinoma of the uterus

Abstract

e16538 Background: Serous carcinoma of the uterus behaves in a much more aggressive fashion than endometrioid tumors of the uterus with risks almost equivalent to ovarian cancers. Given this, we were interested in seeing if pegylated liposomal doxorubicin had a differential benefit in serous cancers of the uterus when compared to endometrioid carcinomas. Methods: Patients with recurrent serous and endometrioid uterine cancer treated with pegylated liposomal doxorubicin between 1999 and 2007 were identified. Demographics, stage, grade, and prior lines of chemotherapy were collected. The primary objectives were to determine progression-free (PFS) and overall survivals (OS) in these subsets of women with recurrent endometrial cancer. Results: Twenty-three patients with recurrent serous histology and 24 with endometrioid histology were identified. The median age at diagnosis in the serous group was 70 (45–89) and 62 (37–94) in the endometrioid cohort. The majority of patients in both groups were Caucasian. There was no difference between the serous and endometrioid cohorts by stage with advanced disease in 65% and 73%, respectively (p = 0.95). The majority of patients had 2 prior lines of treatment. The most common prior chemotherapy was carboplatin and paclitaxel. The median number of pegylated liposomal doxorubicin cycles was 4 in both groups. The median PFS was 4.6 months in the serous cohort and 4.7 months in the endometrioid group (p = 0.47). The median overall survival in the serous group was 9.8 months and in the endometrioid group it was 9.6 months (p > 0.5). Conclusions: We did not find a difference in survival endpoints in women with serous versus endometrioid histologies. While pegylated liposomal doxorubicin appears to be equally active in these groups, survival is uniformly poor in the context of recurrent disease. No significant financial relationships to disclose.